Tilray | TRLY - Cost Of Sales


Tilray reported $164.37M in Cost of Sales for its fiscal quarter ending in September of 2025.





Cost Of Sales Change Date
Akebia Therapeutics USD 10.34M 441K Dec/2025
Alaunos Therapeutics USD 0 18K Sep/2024
Aurora Cannabis CAD 8.22M 80.38M Mar/2026
Avita Medical AUD 3.3M 166K Dec/2025
Canopy Growth CAD 62.98M 9.91M Mar/2026
Cronos Group USD 26.48M 2.26M Mar/2026
Divis Laboratories Ltd INR 12.39B 1.76B Mar/2026
Ionis Pharmaceuticals USD 3M 5M Mar/2026
IQVIA Holdings USD 3.08B 161M Mar/2026
Knight Therapeutics CAD 82.22M 1.03M Dec/2025
Moderna USD 955M 503M Mar/2026
Organigram Holdings CAD 43.39M 13.54M Mar/2026
Organon & Co USD 677M 89M Mar/2026
Revvity USD 323.46M 26.93M Mar/2026
Tilray USD 164.37M 8.41M Sep/2025
Viatris USD 2.36B 195.9M Mar/2026
Xeris Pharmaceuticals USD 10.57M 3.08M Mar/2026
Zealand Pharma A/S 410K 5K Jun/2025